A 29-year-old woman with flu-like symptoms: Review of influenza diagnosis and treatment

JAMA

Volumn 304, Issue 6, 2010, Pages 671-678

  Barry, M Anita ^a  

^a Boston Public Health Commissions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUSSIVE AGENT; ANTIVIRUS AGENT; CODEINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE;

ADULT; CASE REPORT; FEMALE; FLU LIKE SYNDROME; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; RESPIRATORY VIRUS; REVIEW; SYMPTOM;

EID: 77955349288     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.304.6.671     Document Type: Review

References (120)

1. Dawood FS, Jain S, Finelli L, et al; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-2615.
2. Eurosurveillance Editorial Team. Pandemic alert level 6: scientific criteria for an influenza pandemic fulfilled. Euro Surveill. 2009;14(23):19237.
3. Chan M. World now at the start of 2009 influenza pandemic [press release]. June 11, 2009. http://www.who.int/mediacentre/influenzaAH1N1- presstranscript-20090611.pdf. Accessed July 14, 2010.
4. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1-52.
5. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354(9186):1277-1282.
6. Thompson WW, Moore MR, Weintraub E, et al. Estimating influenza-associated deaths in the United States. Am J Public Health. 2009;99(suppl 2): S225-S230.
7. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181(3):831-837.
8. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-1340.
9. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2): 179-186.
10. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl JMed. 2000;342(4):232-239.
11. Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health. 1982;72(9):1008-1016.
12. Louie JK, Acosta M, Winter K, et al; California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896-1902.
13. Centers for Disease Control and Prevention. Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009. MMWR Morb Mortal Weekly Rep. 2010;58(51):1436-1440.
14. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med. 2009;361(27):2591-2594.
15. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7(4):257-265.
16. Boone SA, Gerba CP. The occurrence of influenza A virus on household and day care center fomites. J Infect. 2005;51(2):103-109.
17. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis. 2006;12(11):1657-1662.
18. Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol. 1979;110 (1):1-6.
19. Han K, Zhu X, He F, et al. Lack of airborne transmission during outbreak of pandemic (H1N1) 2009 among tour group members, China, June 2009. Emerg Infect Dis. 2009;15(10). doi:10.3201/eid1510.091013. http://www.cdc.gov/EID/content/ 15/10/1578.htm. Accessed July 14, 2010.
20. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med. 1966;122(3):800-804.
21. Weiss MM, Weiss PD, Weiss DE, Weiss JB. Disrupting the transmission of influenza a: face masks and ultraviolet light as control measures. Am J Public Health. 2007;97(suppl 1):S32-S37.
22. McLean DM, Roy TE, O'Brien MJ, Wyllie JC, McQueen EJ. Para-influenza viruses in association with acute laryngotracheobronchitis, Toronto, 1960-61. Can Med Assoc J. 1961;85:290-294.
23. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA. 2009; 302(17):1865-1871.
24. Yang Y, Sugimoto JD, Halloran ME, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science. 2009;326(5953):729-733.
25. Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med. 2002;162(16):1842-1848.
26. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189(3):440-449.
27. Welliver R, Monto AS, Carewicz O, et al; Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748-754.
28. Cauchemez S, Donnelly CA, Reed C, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med. 2009; 361(27):2619-2627.
29. Lessler J, Reich NG, Cummings DA, Nair HP, Jordan HT, Thompson N; New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med. 2009;361(27):2628-2636.
30. Centers for Disease Control and Prevention. Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship - June-July 2009. MMWR Morb Mortal Wkly Rep. 2010;59(6):162-165.
31. Monto AS, Napier JA, Metzner HL. The Tecumseh Study of Respiratory Illness, I: plan of study and observations on syndromes of acute respiratory disease. Am J Epidemiol. 1971;94(3):269-279.
32. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med. 1978;298(11):587-592.
33. Monto AS, Koopman JS, Longini IM Jr. Tecumseh Study of Illness, XIII: influenza infection and disease, 1976-1981. Am J Epidemiol. 1985;121(6):811-822.
34. Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness, IX: occurrence of influenza in the community, 1966-1971. Am J Epidemiol. 1975; 102(6):553-563.
35. Brownstein JS, Kleinman KP, Mandl KD. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. Am J Epidemiol. 2005;162(7):686-693.
36. Treanor J. The influenza virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Amsterdam, Netherlands: Elsevier; 2005:2060-2085.
37. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol. 2007;28(9):1071-1076.
38. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492-500.
39. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981; 144(5):433-441.
40. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355 (24):2513-2522.
41. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243-3247.
42. Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000;31(5): 1166-1169.
43. Ebell MH, White LL, Casault T. A systematic review of the history and physical examination to diagnose influenza. J Am Board Fam Pract. 2004;17(1): 1-5.
44. Carrat F, Tachet A, Rouzioux C, Housset B, Valleron AJ. Evaluation of clinical case definitions of influenza: detalied investigation of patients during the 1995-1996 epidemic in France. Clin Infect Dis. 1999;28(2):283-290.
45. Cao B, Li X-W, Mao Y, et al; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009; 361(26):2507-2517.
46. Ong AK, Chen MI, Lin L, et al. Improving the clinical diagnosis of influenza: a comparative analysis of new influenza A (H1N1) cases. PLoS One. 2009;4(12): e8453.
47. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-1887.
48. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872-1879.
49. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161(17): 2116-2122.
50. Petric M, Comanor L, Petti CA. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis. 2006; 194(suppl 2):S98-S110.
51. Pérez-Ruiz M, Yeste R, Ruiz-Pérez M-J, Ruiz-Bravo A, de la Rosa-Fraile M, Navarro-Marí JM. Testing of diagnostic methods for detection of influenza virus for optimal performance in the context of an influenza surveillance network. J Clin Microbiol. 2007;45(9):3109-3110.
52. Harper SA, Bradley JS, Englund JA, et al; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(8):1003-1032.
53. Centers for Disease Control and Prevention. Rapid diagnostic testing for influenza. http://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm. Accessed July 14, 2010.
54. Cruz AT, Cazacu AC, Greer JM, Demmler GJ. Rapid assays for the diagnosis of influenza A and B viruses in patients evaluated at a large tertiary care children's hospital during two consecutive winter seasons. J Clin Virol. 2008;41(2):143-147.
55. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol. 2007;39(2):132-135.
56. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48(9):e89-e92.
57. McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis. 2009;48(suppl 1):S14-S19.
58. Centers for Disease Control and Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071- 1074.
59. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis. 2008;14(8):1193-1199.
60. Chien Y-W, Klugman KP, Morens DM. Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med. 2009;361(26):2582-2583.
61. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19(3):571-582.
62. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-970.
63. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000; 283(4):499-505.
64. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329.
65. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32(12):1784-1791.
66. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(suppl 1):S3-S13.
67. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284-3292.
68. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med. 2005;353(25):2633-2636.
69. Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA. 2007;297(13):1492-1493.
70. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA. 2009;301(10):1066-1069.
71. Dharan NJ, Gubareva LV, Meyer JJ, et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301(10):1034-1041.
72. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus. JAMA. 2009;301(10):1042-1046.
73. Centers for Disease Control and Prevention. Flu activity and surveillance: reports and surveillance methods in the United States. http://www.cdc.gov/flu/weekly/fluactivity.htm. Accessed October 13, 2009.
74. Roche Laboratories. Tamiflu (oseltamivir phosphate): capsules and for oral suspension. January 2008. http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM147992.pdf. Accessed July 1, 2010.
75. Hayden FG, Osterhaus AD, Treanor JJ, et al; GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med. 1997;337(13):874-880.
76. Aoki FY, Hayden H, Dolin R. Antiviral drugs (other than antiretrovirals). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Amsterdam, Netherlands: Elsevier; 2010:573-576.
77. Treanor JJ, Hayden FG, Vrooman PS, et al; US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;283(8):1016-1024.
78. Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009;66(5):469-480.
79. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106.
80. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14):1667-1672.
81. Beigel JH, Farrar J, Han AM, et al; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353(13):1374-1385.
82. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568-1575.
83. Lee N, Cockram CS, Chan PK, Hui DS, Choi KW, Sung JJ. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis. 2008;46(8):1323-1324.
84. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333(14):889- 893.
85. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281(10):908-913.
86. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361(13):1260-1267.
87. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005;165(3):274-280.
88. Herrera GA, Iwane MK, Cortese M, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine. 2007;25(1):154-160.
89. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18(26):3040-3049.
90. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262(6):779-783.
91. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant. 1999; 18(3):220-225.
92. Madan RP, Tan M, Fernandez-Sesma A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis. 2008;46(5):712-718.
93. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med. 1996;156(14):1546-1550.
94. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006; 166(20):2217-2221.
95. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984; 119(6):841-879.
96. Schonberger LB, Bregman D, Sullivan-Bolyai JZ, Bryan L, Noble GR. Guillain-Barré syndrome after administration of killed vaccines. Dev Biol Stand. 1977; 39:295-296.
97. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. JAMA. 1982;248(6):698-700.
98. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292(20):2478-2481.
99. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis. 2004;39(7):920-927.
100. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282(2):137-144.
101. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7): 685-696.
102. Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009;301(9):945-953.
103. MedImmune. FluMist prescribing information. http://www.medimmune.com/pdf/ products/flumist-pi.pdf. Accessed July 2, 2010.
104. Vesikari T, Karvonen A, Korhonen T, et al; CAIV-T Transmission Study Group. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25(7):590-595.
105. Lu P, Bridges CB, Euler GL, Singleton JA. Influenza vaccination of recommended adult populations, US, 1989-2005. Vaccine. 2008;26(14):1786-1793.
106. Pearson ML, Bridges CB, Harper SA; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee(HICPAC)and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-2):1-16.
107. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: 7 truths we must accept. Vaccine. 2005;23(17-18):2251-2255.
108. Schiller J, Euler G. Vaccination Coverage Estimates From the National Health Interview Survey: United States, 2008. Atlanta, GA: National Center for Health Statistics; July 2009. http://www.cdc.gov/nchs/data/hestat/vaccine- coverage/vaccine-coverage.pdf. Accessed July 14, 2010.
109. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010; 303(10):943-950.
110. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of influenza vaccines. http://www.cdc.gov/vaccines/ recs/provisional/downloads/flu-vac-mar-2010-508.pdf. Accessed March 20, 2010.
111. Hayden FG, Gubareva LV, Monto AS, et al; Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med. 2000; 343(18):1282-1289.
112. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186(11):1582-1588.
113. Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50(5):707-714.
114. MacIntyre CR, Cauchemez S, Dwyer DE, et al. Face mask use and control of respiratory virus transmission in households. Emerg Infect Dis. 2009;15(2): 233-241.
115. Cowling BJ, Fung RO, Cheng CK, et al. Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS One. 2008;3(5):e2101.
116. Kilbourne ED. Influenza immunity: new insights from old studies. J Infect Dis. 2006;193(1):7-8.
117. Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine. 2007;25(16):3175-3178.
118. Antiviral therapy for influenza: challenging the status quo. Clin Infect Dis. 2009;48(suppl 1):S1-S2.
119. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361(23):2204-2207.
120. Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis. 2007;196(2):181-190.